Show simple item record

dc.contributor.authorSheppard, EC
dc.contributor.authorMorrish, RB
dc.contributor.authorDillon, MJ
dc.contributor.authorLeyland, R
dc.contributor.authorChahwan, R
dc.date.accessioned2021-09-16T14:32:41Z
dc.date.available2021-09-16T14:32:41Z
dc.date.issued2018
dc.identifier.issn1664-3224
dc.identifier.issn1664-3224
dc.identifier.otherARTN 355
dc.identifier.urihttp://hdl.handle.net/10026.1/17803
dc.description.abstract

Epigenetic modifications, such as histone modifications, DNA methylation status, and non-coding RNAs (ncRNA), all contribute to antibody maturation during somatic hypermutation (SHM) and class-switch recombination (CSR). Histone modifications alter the chromatin landscape and, together with DNA primary and tertiary structures, they help recruit Activation-Induced Cytidine Deaminase (AID) to the immunoglobulin (Ig) locus. AID is a potent DNA mutator, which catalyzes cytosine-to-uracil deamination on single-stranded DNA to create U:G mismatches. It has been shown that alternate chromatin modifications, in concert with ncRNAs and potentially DNA methylation, regulate AID recruitment and stabilize DNA repair factors. We, hereby, assess the combination of these distinct modifications and discuss how they contribute to initiating differential DNA repair pathways at the Ig locus, which ultimately leads to enhanced antibody-antigen binding affinity (SHM) or antibody isotype switching (CSR). We will also highlight how misregulation of epigenomic regulation during DNA repair can compromise antibody development and lead to a number of immunological syndromes and cancer.

dc.format.extent355-
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.subjectepigenetic modifications
dc.subjectepigenomics and epigenetics
dc.subjectantibody diversity
dc.subjectcytosine deamination
dc.subjectsomatic hypermutation
dc.subjectclass-switch recombination
dc.subjectB cell maturation
dc.titleEpigenomic Modifications Mediating Antibody Maturation
dc.typejournal-article
dc.typeReview
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29535729
plymouth.issueFEB
plymouth.volume9
plymouth.publication-statusPublished online
plymouth.journalFrontiers in Immunology
dc.identifier.doi10.3389/fimmu.2018.00355
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeSwitzerland
dcterms.dateAccepted2018-02-08
dc.identifier.eissn1664-3224
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.3389/fimmu.2018.00355
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV